“To speak to medical professionals who specialise in sports injury was a breath of fresh air. The experience for me was the best it could be, especially as an athlete with a potentially career-ending injury. Everyone was caring and I was given the hope I so badly needed. It was now possible that... Read More”
Intra-articular protein therapy
nSTRIDE Autologous Protein Solution (APS) therapy is a single protein injection, harvested from a patient’s blood. The treatment is designed to treat pain and slow the progression of cartilage degradation and destruction of the knee in patients with osteoarthritis.
This groundbreaking procedure involves the extraction of blood from the patient, separation in a centrifuge to obtain a concentrated suspension of platelets via plasmapheresis, followed by injection of part of the fluid into the knee.
Osteoarthritis, the most common type of arthritis is a progressive disease of the joints. Osteoarthritis occurs when the top layer of cartilage, the slippery tissue that covers the ends of the bones in a joint and help absorb the shock of movement, breakdown and wears away. This causes the bones to rub together causing pain, swelling and less comfortable movement. Later stages in the disease cartilage will disintegrate and subchrondral microfractures will expose the bony surface.
So once osteoarthritis pain starts it is hard to stop. The nSTRIDE APS Kit is designed to produce a groundbreaking autologous therapy to treat pain and slow the progression of cartilage degradation and destruction in the knee.
The nSTRIDE APS Kit is a self-contained, sterile-packaged, single-use device system. It is designed to separate anti-inflammatory cytokines and growth factors from whole blood. The device system is to be used at the point of care to create an autologous solution.
The nSTRIDE APS Kit uses a small sample of the patient’s own blood to create an autologous solution. This device system consists of two parts: the nSTRIDE Cell Separator and the nSTRIDE Concentrator. The nSTRIDE Cell Separator utilizes centrifugal force to process the blood sample and separate the cellular components from plasma and red blood cells. This step takes 15 minutes. The cell suspension is then loaded into the nSTRIDE Concentrator, which uses centrifugal filtration through polyacrylamide beads to concentrate the injectable output. This step takes 2 minutes.
The final product contains concentrated white blood cells, platelets, and plasma proteins in a small volume of plasma. The output is approximately a 2 to 3 cc anti-inflammatory solution.
The proposed APS mechanism of action is a process of reducing OA-related upregulated inflammatory cytokines by introducing antagonistic cytokines, which inhibit the inflammatory cytokine activity. APS has been shown to reduce production of proteins associated with osteoarthritic inflammation and pain responses in vitro.
There is growing evidence to support its use for select indications in osteoarthritis (Kellgren-Lawrence Grade 2-3). Clinical studies have demonstrated the effectiveness of one single injection. Studies suggest one injection can last at least 12 months, with new evidence shows evidence upto 2 years post injection.
How is nSTRIDE APS given?
The 2 – 3 cc of fluid concentrate is injected directly in the knee joint.
Are there any side effects?
You may experience side effects (e.g. bruising, local pain or swelling) associated with the blood draw, knee injection, MRI or X-Ray procedures.
Will nSTRIDE APS cure my osteoarthritis?
There is no cure for osteoarthritis however successful treatment with nSTRIDE APS may reduce or relieve your pain increasing your mobility and comfort. Your osteoarthritis may not improve or may get worse.
When will the treatment start to work?
Pain relief can be expected after one week.
How long can I expect the benefits to last?
Based on preclinical and early clinical results, patients should expect to see benefits for at least 12 months.